Should I leave Natera for Progenity?

[anonymous]

Hahahhahahah! What?! You are a true idiot. Verifi is from Illumina and is the same test Progenity sells, hence Verifi by Progenity. Same test Labcorp, Quest, Goodstart, Couynsl, etc sell. I think there are about 16 crap labs selling that re-packaged middle of the pack crap NIPT. Have some knowledge of the industry before you come on this board son. You must be an "independent rep" selling this crap test to our offices that all the physicians make fun of for your lack of knowledge. Ie, Atlas Genomics etc..

Do they still send it to Illumina or they're licensed to run it in house now?

 

[anonymous]

Do they still send it to Illumina or they're licensed to run it in house now?

Licensed to run it in house. It's like borrowing someone's computer to use. Same computer, just someone else using it in a different location. Actually, it was a genius idea by Illumina to franchise their product out and make a ton of money to have other labs do their dirty work while they take a % of every test. A gold mine.

 

[anonymous]

Hahahhahahah! What?! You are a true idiot. Verifi is from Illumina and is the same test Progenity sells, hence Verifi by Progenity. Same test Labcorp, Quest, Goodstart, Couynsl, etc sell. I think there are about 16 crap labs selling that re-packaged middle of the pack crap NIPT. Have some knowledge of the industry before you come on this board son. You must be an "independent rep" selling this crap test to our offices that all the physicians make fun of for your lack of knowledge. Ie, Atlas Genomics etc..

no one has made fun of me for lack of anything, but they do snicker at the rather high turn over with your outfit; as well as lack of organization, follow up, etc. I've even seen OM's throw business cards in the trash can with natera on it. I've never spoken negative about any person or any competitor. I just let my clients do that for me with great satisfaction.....ass-wipe. you must be one of those lovable managers everyone wants to take a swipe at. Also, if you took the time to research brainiac, you'd know there is a slight variation on different versions. Granted, not a large one, but still a slight difference. my company has several former natera reps. the training they received at natera is pitiful. the management guidance at natera is atrocious. i can't wait to see a resume with natera management on it. kharma........

 

[anonymous]

no one has made fun of me for lack of anything, but they do snicker at the rather high turn over with your outfit; as well as lack of organization, follow up, etc. I've even seen OM's throw business cards in the trash can with natera on it. I've never spoken negative about any person or any competitor. I just let my clients do that for me with great satisfaction.....ass-wipe. you must be one of those lovable managers everyone wants to take a swipe at. Also, if you took the time to research brainiac, you'd know there is a slight variation on different versions. Granted, not a large one, but still a slight difference. my company has several former natera reps. the training they received at natera is pitiful. the management guidance at natera is atrocious. i can't wait to see a resume with natera management on it. kharma........

Oh yay! Please enlighten me of the "variation" you speak of that makes your verify platform better than or different from illumina's original. Also, please cite some kind of study I can look at that validates any change you have. I'm so curious to learn more! Also, does your NIPT have the lowest failure rate because you make calls in "suspected aneuploidy"? I would love to know what PPV your "different" verifi tests performs at for 21, 18, and 13. Please let me know....I am hungry for some crow, so make me eat it. I'll wait......

 

[anonymous]

no one has made fun of me for lack of anything, but they do snicker at the rather high turn over with your outfit; as well as lack of organization, follow up, etc. I've even seen OM's throw business cards in the trash can with natera on it. I've never spoken negative about any person or any competitor. I just let my clients do that for me with great satisfaction.....ass-wipe. you must be one of those lovable managers everyone wants to take a swipe at. Also, if you took the time to research brainiac, you'd know there is a slight variation on different versions. Granted, not a large one, but still a slight difference. my company has several former natera reps. the training they received at natera is pitiful. the management guidance at natera is atrocious. i can't wait to see a resume with natera management on it. kharma........

Bro, the fact that you said there was a new NIPT that hit the market and it's called Verifi, just lost you ALLLLLL your credibility. What a joke..

 

[anonymous]

doesn't matter shit bags. another new nipt test is already out. called verify. so far, it has the lowest test failure in its class. reports in 2 - 3 days. see ya........

 

[anonymous]

There is this new drug out there called penicillin as well...look into, they may be looking for reps and could be hot!

 

[anonymous]

There is this new drug out there called penicillin as well...look into, they may be looking for reps and could be hot!

No, he is actually looking to get in on the ground floor with Pfizer. He hears they have a new pill that help men get aroused and he's all about that! It just hit the market and is best in class!

Hahaha. It's actually so sad that these shit lab companies employ these reps who know absolutely nothing about the industry or science.

 

[anonymous]

Oh yay! Please enlighten me of the "variation" you speak of that makes your verify platform better than or different from illumina's original. Also, please cite some kind of study I can look at that validates any change you have. I'm so curious to learn more! Also, does your NIPT have the lowest failure rate because you make calls in "suspected aneuploidy"? I would love to know what PPV your "different" verifi tests performs at for 21, 18, and 13. Please let me know....I am hungry for some crow, so make me eat it. I'll wait......

ok, d-bags. Sheeesh. sounds like a bunch of nagging women. I was in an office and actually saw a brochure ( swiped it ) about what you're all talking about. Verify.....let's see. 21 = N = 577 = sensit = 99.14% = observed spec = 99.94%. T21 = observed PPV = 0.970. ONPV = 0.999. Low test failure 0.1%. Now, let's pretend I don't know anything from nothing. Are these the exact same numbers as everyone else's?

 

[anonymous]

ok, d-bags. Sheeesh. sounds like a bunch of nagging women. I was in an office and actually saw a brochure ( swiped it ) about what you're all talking about. Verify.....let's see. 21 = N = 577 = sensit = 99.14% = observed spec = 99.94%. T21 = observed PPV = 0.970. ONPV = 0.999. Low test failure 0.1%. Now, let's pretend I don't know anything from nothing. Are these the exact same numbers as everyone else's?

Yeah. Where's that shit-ass company cheerleader who seems to know everything. I'd like to know, too. Are these the exact same numbers you said it was?

 

[anonymous]

No, he is actually looking to get in on the ground floor with Pfizer. He hears they have a new pill that help men get aroused and he's all about that! It just hit the market and is best in class!

Hahaha. It's actually so sad that these shit lab companies employ these reps who know absolutely nothing about the industry or science.

doesn't sound like it helped you. alot of lonely nights?

 

[anonymous]

Yeah. Where's that shit-ass company cheerleader who seems to know everything. I'd like to know, too. Are these the exact same numbers you said it was?

I'd like to know too. Answer da man, ass-wipe.

 

[anonymous]

Yeah. Where's that shit-ass company cheerleader who seems to know everything. I'd like to know, too. Are these the exact same numbers you said it was?

wanna know too........maybe got his nuts in a bunch. or, is that considered an oxymoron?

 

[anonymous]

Natera facing several law suits
can you say SEC ?
they losing markets like canada
they are losing lowrisk volumes to Sequenom
CMS using CPTs for Ariosa and Sequenom
Natera is toast YE

 

[anonymous]

Natera facing several law suits
can you say SEC ?
they losing markets like canada
they are losing lowrisk volumes to Sequenom
CMS using CPTs for Ariosa and Sequenom
Natera is toast YE

I have no doubt what you say is true, BUT.......what I'm really waiting for is for the company d-bag cheerleader to come out here and explain all of this as nonsense and every company goes through growing pains and all is well with our company.

 

[anonymous]

Shows how much you know ya little minion...How does it feel so low on the todem pole that you actually have no idea what you are talking about? Has it happened yet? No, but the position and stage is set for it to take place and many insurances are going to provide a payment for low risk within the next couple of years. Shit doesn't happen overnight tinkle berry. Go back to your every day life of sucking at field sales and checking Med Reps for the next best opportunity.

Your ignorance is showing or possibly the fact that you drink a lot of Koolaid. For someone who has been in the lab (esoteric/personalized medicine/genetic/somatic etc) industry for 15+ years we have been through this cycle before.

With the additional pressure of being in network from insurances, the elimination and action to go after companies that alter, minimize, cap or alter copays and deductibles it will be biz as usual for the mid/large reference labs. Any specialty labs will be suffering and looking for someway to stay in biz. Mainly b/c their test can be offered by other labs that have a wider breath of menu, which will lead to deeper discounts through volume contracts.

Ideally this is one of two approaches for any of these specialty labs. 1) Raise capital to stay in biz from investors (could perpetuate things for a little while) 2) Go public to raise funds and use test volume and growth as an example of success although reimbursements wont' follow the test volume due to contract status or utilizing testing outside of clinically determined areas of utilization 3) Thrive off of medicare/medicaid populations of testing where OOP costs to patient doesn't exist....although you better have medicare/medicaid contracts 4) Offer testing to a subset of patients that would "like" to have the testing but can't with other labs due to the legality of copays deductibles etc. NIPT for low risk is a great example of this (often illegal pricing and adjustments of copays/deductibles) Unfortunately, this is also the subset of patients that typically are not reimbursed therefore sales are artificial and leads to very little profit of any sort based on the volume they crank out.

End all be all is that the insurances will contract with fewer labs for deeper discount contracts in an attempt to reduce cost by a very slight margin. The only saving grace is if you truly have a clinical viable test that is propriety. A few examples are: BRCAnalysis (before the supreme court knocked it down for monopoly), Oncotype Dx (before copy cats started to arise), 4KScore (good current example but will be mimicked before to long) etc. NIPT for a span of 2 years before it was copied endlessly.

Typically, these companies with propriety test have protection for a short period of time until the process can be reverse engineered or until a larger lab makes something that it is "close enough" to steal testing away. They will also use it as an opportunity to not contract with those labs stating there is no difference in the larger reference labs version vs the specialty lab with the proprietary test.

As a rep all we can do is find a good speciality test that is proprietary or unique....ride the success for a few year then rinse and repeat.

The larger reference labs will always have the advantage with the insurance companies. Unfortunately they are also the ones that pay like crap and have management that is so dogmatic they only succeed by being cheap and sticking around longer than the others. These management teams rarely change b/c no one that can actually sell sticks around long enough to move up.

 

[anonymous]

doesn't matter shit bags. another new nipt test is already out. called verify. so far, it has the lowest test failure in its class. reports in 2 - 3 days. see ya........

OH MY this is priceless. Proves that a lot of sales ppl out there are morons and no nothing other than what their managements and directors tell them. Sad for us reps that actually know something besides how to parrot a sales message. And we wonder why sales reps get a bad wrap from the medical community.

 

[anonymous]

Shows how much you know ya little minion...How does it feel so low on the todem pole that you actually have no idea what you are talking about? Has it happened yet? No, but the position and stage is set for it to take place and many insurances are going to provide a payment for low risk within the next couple of years. Shit doesn't happen overnight tinkle berry. Go back to your every day life of sucking at field sales and checking Med Reps for the next best opportunity.

Your ignorance is showing or possibly the fact that you drink a lot of Koolaid. For someone who has been in the lab (esoteric/personalized medicine/genetic/somatic etc) industry for 15+ years we have been through this cycle before.

With the additional pressure of being in network from insurances, the elimination and action to go after companies that alter, minimize, cap or alter copays and deductibles it will be biz as usual for the mid/large reference labs. Any specialty labs will be suffering and looking for someway to stay in biz. Mainly b/c their test can be offered by other labs that have a wider breath of menu, which will lead to deeper discounts through volume contracts.

Ideally this is one of two approaches for any of these specialty labs. 1) Raise capital to stay in biz from investors (could perpetuate things for a little while) 2) Go public to raise funds and use test volume and growth as an example of success although reimbursements wont' follow the test volume due to contract status or utilizing testing outside of clinically determined areas of utilization 3) Thrive off of medicare/medicaid populations of testing where OOP costs to patient doesn't exist....although you better have medicare/medicaid contracts 4) Offer testing to a subset of patients that would "like" to have the testing but can't with other labs due to the legality of copays deductibles etc. NIPT for low risk is a great example of this (often illegal pricing and adjustments of copays/deductibles) Unfortunately, this is also the subset of patients that typically are not reimbursed therefore sales are artificial and leads to very little profit of any sort based on the volume they crank out.

End all be all is that the insurances will contract with fewer labs for deeper discount contracts in an attempt to reduce cost by a very slight margin. The only saving grace is if you truly have a clinical viable test that is propriety. A few examples are: BRCAnalysis (before the supreme court knocked it down for monopoly), Oncotype Dx (before copy cats started to arise), 4KScore (good current example but will be mimicked before to long) etc. NIPT for a span of 2 years before it was copied endlessly.

Typically, these companies with propriety test have protection for a short period of time until the process can be reverse engineered or until a larger lab makes something that it is "close enough" to steal testing away. They will also use it as an opportunity to not contract with those labs stating there is no difference in the larger reference labs version vs the specialty lab with the proprietary test.

As a rep all we can do is find a good speciality test that is proprietary or unique....ride the success for a few year then rinse and repeat.

The larger reference labs will always have the advantage with the insurance companies. Unfortunately they are also the ones that pay like crap and have management that is so dogmatic they only succeed by being cheap and sticking around longer than the others. These management teams rarely change b/c no one that can actually sell sticks around long enough to move up.

Totem pole...by the way.

 

[anonymous]

Your ignorance is showing or possibly the fact that you drink a lot of Koolaid. For someone who has been in the lab (esoteric/personalized medicine/genetic/somatic etc) industry for 15+ years we have been through this cycle before.

With the additional pressure of being in network from insurances, the elimination and action to go after companies that alter, minimize, cap or alter copays and deductibles it will be biz as usual for the mid/large reference labs. Any specialty labs will be suffering and looking for someway to stay in biz. Mainly b/c their test can be offered by other labs that have a wider breath of menu, which will lead to deeper discounts through volume contracts.

Ideally this is one of two approaches for any of these specialty labs. 1) Raise capital to stay in biz from investors (could perpetuate things for a little while) 2) Go public to raise funds and use test volume and growth as an example of success although reimbursements wont' follow the test volume due to contract status or utilizing testing outside of clinically determined areas of utilization 3) Thrive off of medicare/medicaid populations of testing where OOP costs to patient doesn't exist....although you better have medicare/medicaid contracts 4) Offer testing to a subset of patients that would "like" to have the testing but can't with other labs due to the legality of copays deductibles etc. NIPT for low risk is a great example of this (often illegal pricing and adjustments of copays/deductibles) Unfortunately, this is also the subset of patients that typically are not reimbursed therefore sales are artificial and leads to very little profit of any sort based on the volume they crank out.

End all be all is that the insurances will contract with fewer labs for deeper discount contracts in an attempt to reduce cost by a very slight margin. The only saving grace is if you truly have a clinical viable test that is propriety. A few examples are: BRCAnalysis (before the supreme court knocked it down for monopoly), Oncotype Dx (before copy cats started to arise), 4KScore (good current example but will be mimicked before to long) etc. NIPT for a span of 2 years before it was copied endlessly.

Typically, these companies with propriety test have protection for a short period of time until the process can be reverse engineered or until a larger lab makes something that it is "close enough" to steal testing away. They will also use it as an opportunity to not contract with those labs stating there is no difference in the larger reference labs version vs the specialty lab with the proprietary test.

As a rep all we can do is find a good speciality test that is proprietary or unique....ride the success for a few year then rinse and repeat.

The larger reference labs will always have the advantage with the insurance companies. Unfortunately they are also the ones that pay like crap and have management that is so dogmatic they only succeed by being cheap and sticking around longer than the others. These management teams rarely change b/c no one that can actually sell sticks around long enough to move up.

What the hell is this?

 

[anonymous]

Your ignorance is showing or possibly the fact that you drink a lot of Koolaid. For someone who has been in the lab (esoteric/personalized medicine/genetic/somatic etc) industry for 15+ years we have been through this cycle before.

With the additional pressure of being in network from insurances, the elimination and action to go after companies that alter, minimize, cap or alter copays and deductibles it will be biz as usual for the mid/large reference labs. Any specialty labs will be suffering and looking for someway to stay in biz. Mainly b/c their test can be offered by other labs that have a wider breath of menu, which will lead to deeper discounts through volume contracts.

Ideally this is one of two approaches for any of these specialty labs. 1) Raise capital to stay in biz from investors (could perpetuate things for a little while) 2) Go public to raise funds and use test volume and growth as an example of success although reimbursements wont' follow the test volume due to contract status or utilizing testing outside of clinically determined areas of utilization 3) Thrive off of medicare/medicaid populations of testing where OOP costs to patient doesn't exist....although you better have medicare/medicaid contracts 4) Offer testing to a subset of patients that would "like" to have the testing but can't with other labs due to the legality of copays deductibles etc. NIPT for low risk is a great example of this (often illegal pricing and adjustments of copays/deductibles) Unfortunately, this is also the subset of patients that typically are not reimbursed therefore sales are artificial and leads to very little profit of any sort based on the volume they crank out.

End all be all is that the insurances will contract with fewer labs for deeper discount contracts in an attempt to reduce cost by a very slight margin. The only saving grace is if you truly have a clinical viable test that is propriety. A few examples are: BRCAnalysis (before the supreme court knocked it down for monopoly), Oncotype Dx (before copy cats started to arise), 4KScore (good current example but will be mimicked before to long) etc. NIPT for a span of 2 years before it was copied endlessly.

Typically, these companies with propriety test have protection for a short period of time until the process can be reverse engineered or until a larger lab makes something that it is "close enough" to steal testing away. They will also use it as an opportunity to not contract with those labs stating there is no difference in the larger reference labs version vs the specialty lab with the proprietary test.

As a rep all we can do is find a good speciality test that is proprietary or unique....ride the success for a few year then rinse and repeat.

The larger reference labs will always have the advantage with the insurance companies. Unfortunately they are also the ones that pay like crap and have management that is so dogmatic they only succeed by being cheap and sticking around longer than the others. These management teams rarely change b/c no one that can actually sell sticks around long enough to move up.

Totem pole...by the way.

shazam....